Please login to the form below

Not currently logged in
Email:
Password:

pay-for-delay

This page shows the latest pay-for-delay news and features for those working in and with pharma, biotech and healthcare.

Tit for tat as PBMs blame pharma for high drug prices

Tit for tat as PBMs blame pharma for high drug prices

The PBMs also cited “pay for delay” and other anti-competitive practices in the pharma industry such as withholding samples from generic manufacturers and tweaking formulations to extend patent life among ... In my experience, that kind of

Latest news

  • Concordia accused of overcharging NHS for thyroid drug Concordia accused of overcharging NHS for thyroid drug

    Last December, Pfizer and Flynn Pharma were ordered to pay £84m after being accused of charging excessive and unfair prices for anti-epilepsy treatment phenytoin sodium capsules, but have appealed the ... ruling. Meanwhile, earlier in 2016 the CMA fined

  • Lundbeck challenge to EC pay-for-delay ruling fails Lundbeck challenge to EC pay-for-delay ruling fails

    The Celexa case judgment was the first in a broad investigation by the EC of pay-for-delay practices by the pharma industry that kicked off in 2010. ... After the Lundbeck case, the Commission fined companies in two other pay-for-delay investigations -

  • Pharma's reputation rises, but pricing still a sore point Pharma's reputation rises, but pricing still a sore point

    Patient group survey sees the industry's corporate reputation increase. ViiV was ranked number 1 for the second year in a row . ... of transparency (particularly on pricing and side effects), pay-for-delay schemes and mismanagement of confidential

  • UK government fines GSK over 'pay-for-delay' deals UK government fines GSK over 'pay-for-delay' deals

    The culmination of the investigation is a £37.6m (around $55m) fine for GSK and smaller penalties for other companies involved in the 'pay-for-delay' scheme, including Merck KGaA and ... The CMA's decision relates to activities between 2001 and 2004 in

  • Servier announces job cuts as pressures mount Servier announces job cuts as pressures mount

    Management will mobilise all means available to minimise the social impact of this project and to identify, in consultation with staff representatives, the most appropriate support solutions for the employees concerned," ... The announcement comes after

More from news
Approximately 4 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    US courts have ruled that some of the patent suit settlements amount to ‘pay-for-delay’ deals, in which the maker of the branded drug is essentially paying a potential biosimilar ... FTC. According to Michael A Carrier, a distinguished professor at

  • Pharma deals in May 2015 Pharma deals in May 2015

    This is not the first such case for Teva, as the FTC also filed suit last September for an alleged pay for delay relating to AndroGel. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell therapies.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
VISFO

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....